Westfield Capital Management CO LP Ascendis Pharma A/S Transaction History

Westfield Capital Management CO LP

$21.2 Billion
Q3 2024

A detailed history of Westfield Capital Management CO LP transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Westfield Capital Management CO LP holds 5,133,766 shares of ASND stock, worth $701 Million. This represents 3.62% of its overall portfolio holdings.

Number of Shares

5,133,766

Previous 4,962,824 3.44%

Holding current value

$701 Million

Previous $677 Million 13.27%

% of portfolio

3.62%

Previous 3.41%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$113.0 - $153.43 $19.3 Million - $26.2 Million	170,942 Added 3.44%	5,133,766 $767 Million
Q2 2024 Aug 14, 2024	BUY	$121.07 - $153.67 $107 Million - $136 Million	887,610 Added 21.78%	4,962,824 $677 Million
Q1 2024 May 10, 2024	BUY	$123.45 - $159.4 $5.5 Million - $7.11 Million	44,580 Added 1.11%	4,075,214 $616 Million
Q4 2023 Feb 09, 2024	BUY	$86.1 - $127.36 $19.7 Million - $29.1 Million	228,457 Added 6.01%	4,030,634 $508 Million
Q3 2023 Nov 13, 2023	BUY	$86.5 - $103.97 $14.7 Million - $17.7 Million	170,465 Added 4.69%	3,802,177 $356 Million
Q2 2023 Aug 11, 2023	BUY	$69.96 - $97.84 $34 Million - $47.5 Million	485,586 Added 15.43%	3,631,712 $324 Million
Q1 2023 May 12, 2023	SELL	$104.9 - $126.78 $1.26 Million - $1.53 Million	-12,042 Reduced 0.38%	3,146,126 $337 Million
Q4 2022 Feb 13, 2023	BUY	$99.42 - $131.97 $24.6 Million - $32.7 Million	247,444 Added 8.5%	3,158,168 $386 Million
Q3 2022 Nov 14, 2022	BUY	$84.03 - $110.23 $10.3 Million - $13.5 Million	122,415 Added 4.39%	2,910,724 $301 Million
Q2 2022 Aug 12, 2022	BUY	$78.08 - $117.61 $12 Million - $18 Million	153,282 Added 5.82%	2,788,309 $259 Million
Q1 2022 May 16, 2022	SELL	$102.18 - $135.75 $603,577 - $801,875	-5,907 Reduced 0.22%	2,635,027 $309 Million
Q4 2021 Feb 10, 2022	BUY	$127.1 - $169.66 $67.3 Million - $89.8 Million	529,441 Added 25.07%	2,640,934 $355 Million
Q3 2021 Nov 12, 2021	BUY	$112.67 - $176.92 $10.8 Million - $16.9 Million	95,566 Added 4.74%	2,111,493 $337 Million
Q2 2021 Aug 10, 2021	BUY	$121.62 - $145.29 $18 Million - $21.5 Million	148,234 Added 7.94%	2,015,927 $265 Million
Q1 2021 May 14, 2021	BUY	$124.92 - $173.33 $17.2 Million - $23.9 Million	137,812 Added 7.97%	1,867,693 $241 Million
Q4 2020 Feb 12, 2021	SELL	$151.2 - $182.76 $9.06 Million - $10.9 Million	-59,893 Reduced 3.35%	1,729,881 $289 Million
Q3 2020 Nov 13, 2020	BUY	$134.29 - $154.32 $47.2 Million - $54.2 Million	351,109 Added 24.41%	1,789,774 $276 Million
Q2 2020 Aug 13, 2020	BUY	$110.87 - $156.01 $8.35 Million - $11.8 Million	75,323 Added 5.52%	1,438,665 $213 Million
Q1 2020 May 14, 2020	BUY	$97.01 - $145.11 $9.95 Million - $14.9 Million	102,586 Added 8.14%	1,363,342 $154 Million
Q4 2019 Feb 13, 2020	BUY	$91.45 - $139.12 $12.5 Million - $19 Million	136,702 Added 12.16%	1,260,756 $175 Million
Q3 2019 Nov 08, 2019	BUY	$95.8 - $118.9 $14.6 Million - $18.1 Million	152,302 Added 15.67%	1,124,054 $108 Million
Q2 2019 Aug 13, 2019	BUY	$107.11 - $132.09 $30.5 Million - $37.7 Million	285,207 Added 41.54%	971,752 $112 Million
Q1 2019 May 14, 2019	BUY	$62.15 - $129.99 $9.16 Million - $19.2 Million	147,425 Added 27.35%	686,545 $80.8 Million
Q4 2018 Feb 08, 2019	SELL	$55.16 - $69.67 $2.35 Million - $2.97 Million	-42,614 Reduced 7.33%	539,120 $33.8 Million
Q3 2018 Nov 14, 2018	BUY	$63.77 - $76.28 $10 Million - $12 Million	157,159 Added 37.02%	581,734 $41.2 Million
Q2 2018 Aug 13, 2018	BUY	$58.55 - $73.92 $24.9 Million - $31.4 Million	424,575 New	424,575 $28.2 Million

Others Institutions Holding ASND

# of Institutions

244

Shares Held

58.8M

Call Options Held

250K

Put Options Held

377K

View Full List

About Ascendis Pharma A/S

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $7.62B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

More about ASND

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Westfield Capital Management CO LP, based on Form 13F filings with the SEC.

News

Stay updated on Westfield Capital Management CO LP with notifications on news.

Account

Westfield Capital Management CO LP Ascendis Pharma A/S Transaction History